Declaration of Voting Results & Voting Rights Announcements • May 12, 2014
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Paris, May 12, 2014 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):
| Date | Total number of outstanding shares |
Total number of voting rights |
|---|---|---|
| April 30, 2014 | 20, 682, 992 | Theoretical number of voting rights: 20, 682, 992 (including treasury shares) Number of real voting rights: 20, 669, 200 (without treasury shares) |
Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going Validive® (Clonidine Lauriad® ) (mucositis): Phase II on going AMEP® (invasive melanoma): Preclinical Phase For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Judith Gréciet, CEO Caroline Carmagnol Tel.: +33 1 45 58 76 01 Tel.: +33 6 64 18 99 59 Judith.grecie[email protected] [email protected]
Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.